Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study

1. In a health examination survey of 2322 men, aged 49–50 years, the prevalence of hypertension was 7·5%. All men with a supine diastolic blood pressure ≥ 105 mmHg were invited to a hypertension clinic. 2. Two years' treatment in eighty-six men achieved a blood pressure reduction of 31/16 mmHg, which was maintained for a 4 years period and considered satisfactory in 80% of the subjects. Propranolol was used in more than 80% of the cases. 3. The study indicates that it is possible to obtain acceptable blood pressure control in the community.

Download Full-text

Aliskiren for the Treatment of Hypertension: An Update

Clinical Medicine Therapeutics ◽

10.4137/cmt.s1991 ◽

2009 ◽

Vol 1 ◽

pp. CMT.S1991

Author(s):

S Lam ◽

S Saxena ◽

LO Macina ◽

PE Lester

Keyword(s):

Blood Pressure ◽

Blood Pressure Control ◽

Disease Risk ◽

Angiotensin Receptor Blockers ◽

Blood Pressure Reduction ◽

Antihypertensive Agents ◽

Pressure Control ◽

Pressure Reduction ◽

Efficacy And Safety ◽

Treatment Of Hypertension

Hypertension can lead to significant morbidity and mortality, and requires lifestyle modifications with or without drug therapy to achieve target blood pressure control. Various classes of anti-hypertensive medications are available to healthcare providers. Choice of medications is based not only on efficacy but also tolerability and cost. Aliskiren is the first drug of a new class of agents known as renin inhibitors. It is approved by the U.S. Food and Drug Administration (FDA) as monotherapy or combination therapy with other antihypertensive agents to optimize blood pressure control. Its efficacy in blood pressure reduction is superior to placebo and comparable to angiotensin receptor blockers, hydrochlorothiazide, angiotensin-converting-enzyme inhibitors and atenolol. It also offers additional blood pressure reduction when used in combination of other agents. Recently, a study demonstrated its efficacy and safety in the elderly, and a study suggested its renoprotective effects in patient who were already taking losartan. More clinical studies are awaited to assess its potential for cardiovascular disease risk reduction. This paper reviews the pharmacology, efficacy and safety of aliskiren for the treatment of hypertension.

Download Full-text

Treatment of hypertension in the 1990s: Optimizing the benefit of blood pressure reduction by minimizing risk factors for cardiovascular disease

The American Journal of Medicine ◽

10.1016/0002-9343(87)90143-4 ◽

1987 ◽

Vol 82 (1) ◽

pp. 44-49 ◽

Cited By ~ 16

Author(s):

Myron H. Weinberger

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Cardiovascular Disease ◽

Blood Pressure Reduction ◽

Pressure Reduction ◽

Treatment Of Hypertension

Download Full-text

Optimization of treatment of hypertension in hypothyroidism: the role and place of angiotensin-converting enzyme inhibitors

Arterial’naya Gipertenziya (Arterial Hypertension) ◽

10.18705/1607-419x-2008-14-3-270-274 ◽

2008 ◽

Vol 14 (3) ◽

pp. 270-274

Author(s):

G. Selivanova

Keyword(s):

Blood Pressure ◽

Enzyme Inhibitors ◽

Blood Pressure Reduction ◽

Angiotensin Converting Enzyme Inhibitors ◽

Pressure Reduction ◽

Converting Enzyme ◽

Thyroid Status ◽

Converting Enzyme Inhibitors ◽

Treatment Of Hypertension ◽

Hypothyroid Patients

The study addresses antihypertensive therapy in 60 hypothyroid patients with hypertension of different degrees. It is documented that 70% of hypertensive in patients with sub compensation of hypothyroidism have stage 3 hypertension. The efficacy of perindopril in these patients is 87,5%. The time necessary for blood pressure reduction is longer in patients with older age, severe hypertensions and lower thyroid status.

Download Full-text